Decurarization After Thoracic Anesthesia using sugammadex compared to neostigmine (DATA trial): a multicenter randomized double-blinded controlled trial

Thoracic surgery is a high-risk surgery especially for the risk of postoperative pulmonary complications. Postoperative residual paralysis has been shown to be a risk factor for pulmonary complications. Nevertheless, there are few data in the literature concerning the use of neuromuscular blocking a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Anesthesia, Analgesia and Critical Care (Online) Analgesia and Critical Care (Online), 2024-02, Vol.4 (1), p.9-9, Article 9
Main Authors: Piccioni, Federico, Rosboch, Giulio L, Coccia, Cecilia, Donati, Ilaria, Proto, Paolo, Ceraolo, Edoardo, Pierconti, Federico, Pagano, Martina, Vernocchi, Daniele, Valenza, Franco, Rocca, Giorgio Della
Format: Article
Language:English
Subjects:
Anesthesia
Chronic obstructive pulmonary disease
Drug dosages
Enrollments
Extubation
Medical personnel
Neostigmine
Neuromuscular blockade
Patients
Postoperative complications
Software
Sugammadex
Surgical outcomes
Thoracic surgery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thoracic surgery is a high-risk surgery especially for the risk of postoperative pulmonary complications. Postoperative residual paralysis has been shown to be a risk factor for pulmonary complications. Nevertheless, there are few data in the literature concerning the use of neuromuscular blocking agent antagonists in patients undergoing lung surgery. Seventy patients were randomized in three Italian centers to receive sugammadex or neostigmine at the end of thoracic surgery according to the depth of the residual neuromuscular block. The primary outcome was the time from reversal administration to a train-of-four ratio (TOFR) of 0.9. Secondary outcomes were the time to TOFR of 1.0, to extubation, to postanesthesia unit (PACU) discharge, postoperative complications until 30 days after surgery, and length of hospital stay. Median time to recovery to a TOFR of 0.9 was significantly shorter in the sugammadex group compared to the neostigmine one (88 vs. 278 s - P 
ISSN:2731-3786
2731-3786
DOI:10.1186/s44158-024-00146-6